Skip to main navigationSkip to main content
The University of Southampton
Southampton Health Technology Assessments CentreNews

NICE guidance informed by SHTAC report on Atezolizumab for treating metastatic urothelial cancer after platinum-based chemotherapy

Published: 29 June 2018
Intravenous chemotherapy
Bladder cancer is the 7th most common cancer in the UK

The National Institute for Health and Care Excellence (NICE) has issued guidance to the national health service (NHS) on the use of the drug Atezolizumab informed by a report produced by SHTAC.

NICE’s guidance recommends atezolizumab as an option for treating locally advanced or metastatic urothelial carcinoma in adults who have had platinum-containing chemotherapy, only if:

  • atezolizumab is stopped at 2 years of uninterrupted treatment or earlier if the disease progresses and
  • the company provides atezolizumab with the discount agreed in the patient access scheme.

NICE’s guidance is informed by an evidence review group report prepared by SHTAC, which critically appraised the drug company’s submission to NICE’s Single Technology Appraisal process.

For more information about SHTAC’s previous research into cancer please visit our Research page.

 

Privacy Settings